Revive inks research agreement to explore use of Bucillamine in treating severe COVID-19
Revive inks research agreement to explore use of Bucillamine in treating severe COVID-19
SeekingAlpha
0 shares
2 views
You might like
Related news coverage
Revive Therapeutics inks feasibility deal with Lohmann Therapie-Systeme to produce an oral psilocybin thin film strip
Proactive Investors
Revive Therapeutics Ltd (CSE:RVV) (OTC:RVVTF) (FRA:31R) has entered into a feasibility agreement with LTS Lohmann Therapie-Systeme..